ACOR Financial Facts
Cost of sales: 13.48MNet loss per share-basic (earnings per share): -0.03
See Full Income Statement
Accumulated deficit: -255.66M
Current portion of convertible notes payable: 1.14M
See Full Balance Sheet
Earnings History for Acorda Therapeutics, Inc. (ACOR)
|
Expand Research on ACOR
| Next EPS Date | 7/30/13 *Est. | EPS Growth Rate | -75.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +108.6% | Revenue Growth Rate | -12.6% *Last Qtr. |
| Average % Move 1-Wk after EPS | -2.1% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/4/11 |
Q311 | $0.40 | $0.73 | -$0.33 | $93.03M | $90.78M | N/A / N/A | N/A | +67.3% | Details | |
| 5/2/13 |
Q113 | $0.09 | $0.13 | -$0.04 | $62.3M | $80.71M | N/A / N/A | N/A | -10.6% | Details | |
| 2/13/13 |
Q412 | $0.24 | $0.15 | +$0.09 | $81.47M | $78.9M | N/A / N/A | N/A | +15.9% | Details | |
| 10/31/12 |
Q312 | $0.38 | $0.10 | +$0.28 | $77.44M | $75.2M | N/A / N/A | N/A | +52.2% | Details | |
| 7/31/12 |
Q212 | $0.27 | $0.12 | +$0.15 | $75.66M | $72.55M | N/A / N/A | N/A | +38.3% | Details | |
| 5/3/12 |
Q112 | $0.36 | $0.18 | +$0.18 | $71.25M | $70.95M | N/A / N/A | N/A | +34.1% | Details | |
| 2/16/12 |
Q411 | $0.45 | $0.18 | +$0.27 | $72.64M | $69.16M | N/A / N/A | N/A | +29.2% | Details | |
| 8/1/11 |
Q211 | $0.19 | $0.12 | +$0.07 | $65.28M | $66.29M | N/A / N/A | N/A | +20.5% | Details |
